Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Does This Genetic Variance Matter in DLBCL Survival?
Clin Lymphoma Myeloma Leuk; ePub 2016 Aug 21; Haws, et al
There were no substantial differences in survival between people with diffuse large B-cell lymphoma with MYC increased copy number (ICN) and those with no MYC in a study involving 76 individuals.
Investigators compared overall survival in participants with MYC ICN (n=33) to MYC negative patients (n=43), looking at the significance of increased MYC gene copy number. Among the results:
• There were no significant differences in survival.
• There was also no difference in survival between those with IHC MYC ≥40% vs IHC MYC<40%.
• Those with MYC ICN showed a slightly increased MYC protein expression.
• There appeared to be better overall survival in patients with Ki-67 >80%, but the difference was not statistically significant.
• Most patients in both groups—8 in every 10—were treated with rituximab based therapies.
Citation: Haws B, Cui W, Person D, Zhang D. Clinical and pathological correlation of increased MYCgene copy number in diffuse large B-cell lymphoma (DLBCL). [Published online ahead of print August 21, 2016]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2016.08.017.